Proteoglycans: A Comprehensive Reference
1. Identity, Nomenclature, and Classification
Proteoglycans are ubiquitous molecules that function as critical components of the extracellular matrix. These molecules are composed of glycosaminoglycan (GAG) chains that are covalently attached to a protein core. More precisely, proteoglycans are proteins that are covalently bonded at multiple sites along the protein chain to a class of polysaccharides known as glycosaminoglycans, which constitute approximately 95% of the mass of proteoglycans by weight. As a consequence, proteoglycans act as polysaccharides rather than proteins, since 95% of their weight is composed of glycosaminoglycan.
Proteoglycans and glycosaminoglycans have the common structural characteristics of linear polysaccharide chains consisting of a hexosamine alternating with another sugar. They play an important role in skin as part of the support matrix of connective tissue, and may be related to cell–cell and cell–matrix interactions. In general the polysaccharide chains are covalently linked to protein and may contain varying amounts of sulfate resulting in a strong negative charge.
The glycosaminoglycan chains consist of alternating hexosamine and hexuronic acid or galactose units. There are also glycopeptide linkage regions that connect the polysaccharide chains to the core proteins, and these contain N- and/or O-linked oligosaccharides.
Proteoglycans are classified according to both their core proteins and the type of GAG chains attached. The major classes are:
- Chondroitin sulfate proteoglycans (CSPGs) / Hyalectans (Lecticans): The first subgroup contains four genes that encode hyalectans, including aggrecan, versican, neurocan, and brevican, which are key structural components of cartilage, blood vessels, and nervous systems.
- Small Leucine-Rich Proteoglycans (SLRPs): The second subgroup includes eighteen small leucine-rich proteoglycans (SLRPs), which perform various functions and signal through different receptors. This family of proteoglycans consists of small homologous core proteins that include one or two glycosaminoglycan chains. These small core proteins include decorin, biglycan, fibromodulin, and others.
- Heparan sulfate proteoglycans (HSPGs): The heparan sulfate proteoglycans (HSPGs) consist of a proteoglycan "core" protein and covalently attached heparan sulfate (HS) chain, and are ubiquitously expressed in mammalian cells on the cell surface and in the extracellular matrix (ECM) and secretory vesicles. The "full-time" HSPGs include the cell-surface-tethered 4 syndecan (SDC1–4) and 6 glypican (GPC1–6) isoforms, the 3 basement membrane- and ECM-localized perlecan, agrin, and collagen type VIII, and one cytoplasmic secretory granule HSPG serglycin.
- Intracellular/Membrane Proteoglycans: Membrane proteoglycans tend to contain mostly heparan sulfate (e.g., the glypicans), but many are hybrid structures containing both heparan sulfate and chondroitin sulfate (e.g., the syndecans and betaglycan). A few membrane proteoglycans contain exclusively chondroitin sulfate (e.g., CD44 and NG2).
The horseshoe-shaped SLRPs (decorin, biglycan, lumican, and fibromodulin) and bottlebrush-structured hyaluronan (HA)-binding proteoglycans (aggrecan, versican, and brevican) are located in the extracellular matrix, whereas glypicans and syndecans are cell surface proteoglycans. All proteoglycans differ in the GAG side chains attached to the core protein, as well as the lengths and sulfation patterns of the GAGs, thus adding to their complexity.
Key Named Proteoglycans
- Aggrecan: The most well-studied proteoglycan, called aggrecan, is found alongside collagen as one of the main components of cartilage. The negative charges on the repeating glycosaminoglycan units of aggrecan attract water absorption. As a result, aggrecan acts as a cushion for impact retention by absorbing and desorbing water. This role is particularly important in joints that sustain high amounts of impact, such as the knees.
- Versican: Versican is a large chondroitin sulfate/dermatan sulfate proteoglycan belonging to the aggrecan/lectican family. In adults, this proteoglycan serves as a structural macromolecule of the extracellular matrix in the brain and large blood vessels. In contrast, versican is transiently expressed at high levels during development and under pathological conditions when the extracellular matrix dramatically changes, including during inflammation and the repair process.
- Decorin: Decorin, which is widely distributed in many connective tissues, may have functions in regulating collagen fibril formation and in modifying the activity of transforming growth factor-beta.
- Perlecan: Perlecan, the major heparan sulfate proteoglycan in the glomerular basement membrane, may play an important role as the major anionic site responsible for charge selectivity in glomerular filtration.
- Neurocan and Brevican: Neurocan and brevican are concentrated particularly in the specialized extracellular matrices of the brain.
Principal Natural Sources
Proteoglycans are present in all members of the Bilateria and therefore have a long evolutionary history. They are widespread components of most tissues and organs and can sometimes be a dominant component (e.g., in the vertebrate cartilage matrix). Studies of proteoglycans initially focused on cartilage, since the major component, now known as aggrecan, is abundant and readily purified.
For dietary supplement purposes, the primary commercial source is salmon nasal cartilage. In Japan, salmon (Oncorhynchus keta) has traditionally been regarded as a fish of which "nothing is wasted," and its various parts have been utilized in diverse ways since ancient times. For over 200 years, salmon has been consumed in preparations such as salted grilled fillets, Izushi (fermented sushi), and simmered backbone, while the viscera are eaten as Mefun, the roe as Ikura, and the head region (Hizu) as Hizunamasu. Other mammalian tissues containing high concentrations of proteoglycans include bovine articular cartilage, porcine tissues, and human annular fibrosus of the intervertebral disc. Proteoglycan preparations from human annular fibrosus contain chondroitin sulfate, keratan sulfate, and hyaluronic acid.
Common Supplement Forms and Preparations
In recent years, proteoglycans derived from sources such as salmon nasal cartilage have gained popularity as dietary supplements and cosmetic ingredients. Commercial preparations include oral capsules, tablets, and functional food products. Salmon proteoglycan is extracted from salmon (Oncorhynchus keta) nasal cartilage. Some products combine salmon nasal cartilage-derived proteoglycan with type II collagen. For example, one clinical product described as "Proteoglycan complex 80" contained 16 mg of proteoglycan and 16 mg of type II collagen derived from salmon.
2. Traditional and Historical Use
Although the specific term "proteoglycan" is relatively modern, traditional medicinal systems—particularly in East Asia—have long utilized extracts from animal cartilage and connective tissues, which are rich sources of proteoglycans, for their reputed health benefits. In traditional Chinese and Japanese remedies, broths and extracts from fish cartilage or shark cartilage were consumed to support joint health, alleviate arthritis symptoms, and promote overall vitality.
Historically, proteoglycans have been valued in traditional medicine, particularly in East Asian countries, where extracts from animal cartilage have been used to support joint and skin health. These practices predate by centuries the molecular characterization of these molecules, as these benefits were observed empirically in past generations, even before the molecular composition of these extracts was fully understood.
Within Japan in particular, the use of salmon head cartilage (the nasal region being especially cartilage-rich) in traditional cuisine created a de facto prolonged exposure of populations to concentrated proteoglycan sources. This culinary tradition has been documented across multiple centuries and across different regions of Japan, and forms the historical basis for the current supplement industry centered on salmon nasal cartilage-derived proteoglycans.
3. Key Constituents and Mechanisms of Action
Core Biochemistry
Proteoglycan architecture is composed of multiple elements: a core protein is covalently decorated with glycosaminoglycan (GAG) chains, and the entire glycoconjugate can be differentially displayed as soluble or cell-surface-anchored molecules. The ribosomally synthesized core protein is enzymatically modified with a tetrasaccharide linker and further elongated. Changes in disaccharide composition and linkages result in the various classes of GAGs, including heparan, chondroitin, dermatan, and keratan sulfate.
Biosynthesis consists of the formation of the protein core followed by the sequential addition of sugars and sulfate to the nonreducing ends of growing chains. The synthetic process is highly organized, with the final polysaccharide polymerization and sulfation taking place in the Golgi. Degradation of the proteoglycans involves endoglycosidases, exoglycosidases, and proteases which work in concert to degrade these substances.
Water-Binding and Biomechanical Function
As a result of the ionic character of glycosaminoglycans, proteoglycans carry at least one negatively charged carboxylate or sulfate functional group under physiological conditions. This charge is central to one of their most important biophysical properties. Aggrecan and versican, two members of large modular proteoglycans or lecticans, and their partner hyaluronan likely provide tendon tissues with a high capacity to resist high compressive and tensile forces associated with loading and mobilization.
Extracellular Matrix Organization and Collagen Interaction
Proteoglycans have distinct biological functions apart from their hydrodynamic functions, and their involvement in many aspects of cell and tissue activities has been demonstrated. For example, decorin may have functions in regulating collagen fibril formation and in modifying the activity of transforming growth factor-beta. Specific interactions between proteoglycans (through both their glycosaminoglycan and core protein components) and macromolecules in the extracellular matrix are the key factors in the functions of proteoglycans.
Decorin, biglycan, fibromodulin, and lumican, all members of the small leucine-rich proteoglycans family, bind to collagen fibrils and are active participants in fibrillogenesis. Versican, a large chondroitin sulfate proteoglycan, promotes collagen fibrillogenesis in a turbidity assay and upregulates cell-mediated collagen compaction and reorganization, whereas aggrecan, a structurally similar large proteoglycan, has different and often opposing effects on collagen.
Growth Factor Binding and Cell Signaling
Within HSPGs, the HS chains mediate most biological roles through binding various protein ligands, including cytokines, chemokines, growth factors and receptors, morphogens, proteases, protease inhibitors, and ECM proteins. Through these interactions, HSPGs modulate cell proliferation, adhesion, migration, invasion, and angiogenesis to display essential functions in physiology and pathology.
GAG chains are heterogeneous in size and composition, and they can encode specificity for growth factors, such as Fibroblast Growth Factor-2 (FGF2).
Anti-Inflammatory Mechanisms
In the context of osteoarthritis and joint disease, preclinical research has identified specific molecular anti-inflammatory actions. Treatment with salmon nasal cartilage-derived proteoglycans significantly improved cartilage structure and decreased inflammation, as evidenced by decreased levels of PGE2 and nitric oxide, as well as reduced expression of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1β, and interleukin-6. Proteoglycan treatment also downregulated matrix metalloproteinases while increasing tissue inhibitors of metalloproteinases, preserving cartilage integrity.
Cartilage Biosynthesis Support
The loss of proteoglycans from articular cartilage is a hallmark in the development of osteoarthritis. It has been proposed that the administration of salmon nasal cartilage proteoglycan may improve the symptoms of knee osteoarthritis, due to its chondroprotective and anti-inflammatory actions. Studies indicate that oral proteoglycan may suppress collagen degradation: administration of salmon nasal cartilage proteoglycan may suppress the degradation of type II collagen, as evidenced by significant reduction of the C1,2C level, in the cartilage of subjects with severe or constant joint discomfort.
Wound Healing Mechanisms
The GAG hyaluronan (HA) and the proteoglycans versican and aggrecan are all partners in the control of the wound healing process. It is now well accepted that the ECM not only provides architectural support for resting tissues, but also undergoes important alterations after injury that are essential for directing cell behavior during the wound healing process. The function of the ECM facilitates repair of the wound either directly by modulating important aspects of cell behavior such as adhesion, migration, proliferation, metabolism, differentiation, and survival, or indirectly by modulating extracellular protease secretion/activation, or by modulating growth factor activity or bioavailability.
4. Scientific Evidence by Area of Use
4.1 Joint Health and Osteoarthritis
This is the most extensively researched application for supplemental proteoglycans and the area with the strongest, though still limited, clinical evidence.
Preclinical Evidence (Animal and In Vitro): Multiple studies in rodent models have demonstrated anti-osteoarthritic effects. One study evaluated the efficacy of salmon nasal cartilage-derived proteoglycans in mitigating osteoarthritis symptoms and investigated the underlying molecular mechanisms, employing a rat model of osteoarthritis induced by monosodium iodoacetate (MIA) injection. The MIA injection caused significant cartilage damage, reduced bone mineral density, and impaired exercise ability — all of which were attenuated by proteoglycan treatment in treated animals.
Human Clinical Evidence — Cartilage Metabolism Biomarkers: A randomized double-blind placebo-controlled clinical trial was conducted to evaluate the chondroprotective action of salmon nasal cartilage proteoglycan on joint health. The effect of oral administration of proteoglycan (10 mg/day) on cartilage metabolism was evaluated in individuals with knee joint discomfort but without a diagnosis of knee osteoarthritis. The average age of patients was 52.6 ± 1.1 years old. The effect of proteoglycan was evaluated by analyzing markers for type II collagen degradation (C1,2C) and synthesis (PIICP), and the ratio of type II collagen degradation to synthesis. The results indicated that the change in C1,2C levels significantly differed in the proteoglycan group compared with the placebo group following 16 weeks' intervention among subjects with high levels of knee pain and physical dysfunction (total score of Japan Knee Osteoarthritis Measure ≥41) and subjects with constant knee pain (both P < 0.05). There was a greater increase in PIICP levels in the proteoglycan group than in the placebo group following intervention, although this difference was not significant in both sets of patients. The C1,2C/PIICP ratios decreased in the proteoglycan group, whereas they slightly increased in the placebo group following the intervention. The authors concluded that oral administration of salmon nasal cartilage proteoglycan at a dose of 10 mg/day may exert a chondroprotective action in subjects with knee joint discomfort.
Human Clinical Evidence — Diagnosed Knee Osteoarthritis: A more recent and clinically significant trial addressed patients with confirmed osteoarthritis. A 24-week randomized, placebo-controlled, double-blind clinical trial with two arms was conducted: (1) Proteoglycan F, in which participants received 10 mg proteoglycan daily for 24 weeks, and (2) a control group receiving placebo. Knee symptoms and joint cartilage status (evaluated by ultrasound and MRI of knee joints), quality of life, serum cytokine levels (IL-1β and TNF-α), and safety evaluation were measured before, during, and after treatment. This was described as the first randomized double-blind placebo-controlled clinical trial to show the efficacy and tolerability of oral administration of salmon nasal proteoglycan on knee OA patients. The relatively modest sample size was acknowledged as a limitation of the study; additionally, patients were recruited and followed during a period when Vietnam was seriously affected by the COVID-19 epidemic, which also increased the number of dropout patients.
Human Clinical Evidence — Knee Discomfort in Healthy Volunteers: In a separate study, 60 healthy males and females aged between 40 and 70 were asked to take a tablet containing Proteoglycan complex 80 (16 mg of proteoglycan and 16 mg of type II collagen derived from salmon) or a placebo over a period of 12 weeks. The study concerned "discomfort when sitting in the traditional Japanese seiza position" (stiffness, discomfort, and pain in the knees when kneeling and sitting on heels), and the results confirmed a significant difference between the two groups.
Previous clinical trials have yielded encouraging findings; specifically, a daily oral dosage of 10 mg/kg of salmon proteoglycan, administered over 16 weeks, demonstrated a chondroprotective effect in subjects suffering from knee pain. Furthermore, another investigation reported that a 12-week regimen of 10 mg/day oral salmon proteoglycan conferred pain relief and improved joint health in individuals with mild knee pain (predominantly Kellgren-Lawrence grade 0–II).
Evidence strength assessment: Evidence for joint health is encouraging but remains at an early stage. Human trials are small, predominantly conducted in Japan and Vietnam, and typically of short duration (12–24 weeks). Most studies are on non-OA participants or mild OA. Larger, multicenter, long-term RCTs are required before firm clinical conclusions can be drawn.
4.2 Skin Health and Anti-Aging
Preclinical: Animal research has provided a foundation for skin-related claims. A study (Goto et al., 2012, referenced in the clinical literature) investigated anti-aging effects of high-molecular-weight proteoglycan from salmon nasal cartilage in hairless mice, providing animal-level support for subsequent human trials.
Human Clinical Evidence — Skin Hydration and Condition: To examine the effect of ingestion of salmon (Oncorhynchus keta, Salmonidae) nasal cartilage-derived proteoglycan (sPG) on skin condition, a randomized, double-blind, controlled study was performed in healthy adult volunteers. Proteoglycan is one of the components of the extracellular matrix with various biological activities and has been used as a functional food to improve knee joint health or skin condition. Recruited subjects (n = 156) were men and women, ages 21–62 years.
Human Clinical Evidence — Facial Anti-Aging: A study aimed to evaluate the efficacy of oral proteoglycan supplementation in enhancing skin elasticity, hydration, and reducing roughness, wrinkles, and pigmentation in healthy adult volunteers. A 56-day randomized, double-blind, placebo-controlled trial was conducted involving 66 subjects aged 30–60. Subjects received a daily dose of 20 mg proteoglycan. Subjects receiving PG supplementation showed significant improvements in skin elasticity and hydration at both 28 days and 56 days (p < 0.001), with reductions in skin roughness and wrinkles (p < 0.001), and a significant decrease in melanin content and brown spots (p < 0.001). Compared to the placebo group, the PG group exhibited significant improvements in most skin parameters by 56 days, except in the wrinkle area percentage at the crow's feet, where no significant difference was observed. PG was well tolerated, with no adverse effects reported.
These human studies were conducted predominantly on Japanese subjects, with limited research available on other populations. Moreover, previous studies had limitations, such as the specific types of data collection equipment used and the relatively small sample sizes.
Evidence strength assessment: The skin health data is preliminary and encouraging but limited by small sample sizes, short durations (8 weeks or fewer), and the fact that most studies originate from a single country (Japan) and have industry connections. Replication in independent, larger cohorts is needed.
4.3 Wound Healing
The importance of the ECM in the complex processes of wound healing is that it provides architectural support for the tissues and a platform for cells and molecules that regulate inter- and intracellular signaling. ECMs are composed of a dynamic and complex array of glycoproteins, collagens, glycosaminoglycans (GAGs), and proteoglycans (PGs).
Due to their distinct spatial and temporal expression across various cell types — such as epithelial cells, fibroblasts, and immune cells — syndecans (a family of transmembrane heparan sulfate proteoglycans) are well-positioned to coordinate regenerative responses. Research has focused on the spatial regulation of syndecans during skin wound healing, highlighting their roles in epidermal and dermal repair, modulation of intracellular signaling, and remodeling of the wound microenvironment. Overall, syndecans are emerging as central modulators of skin wound healing, with promising implications for regenerative medicine.
The current evidence for wound healing is predominantly mechanistic and preclinical (cell culture and animal models). No large-scale human clinical trials of oral proteoglycan supplementation specifically for wound healing endpoints have been identified in the peer-reviewed literature.
4.4 Central Nervous System
The lectican family — aggrecan, brevican, versican, and neurocan — are extracellular CSPGs that populate the CNS ECM. Neuron-glial antigen 2 (NG2)/chondroitin sulfate proteoglycan 4 (CSPG4), phosphacan, and CD44 are cell-surface CSPGs. The CNS is highly enriched in brevican and NRXN-3 compared with other tissue types.
As a major constituent in the extracellular matrix, proteoglycans participate in neuro-inflammation, modulating the fibrotic process. Research has discussed the functional roles of proteoglycans in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and age-related neurodegeneration. Aggrecan has also been found to play an important role in the central nervous system.
CNS-related proteoglycan research is currently at the basic science stage; no clinical trials of oral supplementation for neurological indications have been established in the peer-reviewed record.
4.5 Cancer Biology
Proteoglycans, which consist of a protein core and glycosaminoglycan chains, are major components of the extracellular matrix and play physiological roles in maintaining tissue homeostasis. In the carcinogenic tissue microenvironment, proteoglycan expression changes dramatically. Altered proteoglycan expression on tumor and stromal cells affects cancer cell signaling pathways, which alters growth, migration, and angiogenesis and could facilitate tumorigenesis.
Through their interactions with cytokines, growth factors, and ECM proteins, HSPGs modulate cell proliferation, adhesion, migration, invasion, and angiogenesis. Under physiological conditions, the expression and localization of HSPGs are finely regulated to orchestrate their physiological functions, and this is disrupted in cancer. Versican has been identified as upregulated in many tumors, including lung, gastric, ovarian, breast, and melanoma.
This area of proteoglycan research concerns endogenous proteoglycan biology as a target for cancer drug development rather than supplementation with exogenous proteoglycans. No clinical evidence supports the use of oral proteoglycan supplements to treat or prevent cancer.
4.6 Cardiovascular and Kidney Function
Versican is a large chondroitin sulfate/dermatan sulfate proteoglycan that, in adults, serves as a structural macromolecule of the extracellular matrix in large blood vessels. Perlecan, the major heparan sulfate proteoglycan in the glomerular basement membrane, may play an important role as the major anionic site responsible for charge selectivity in glomerular filtration. These functions are endogenous biological roles; current evidence is mechanistic, with no clinical trials demonstrating benefit from supplemental proteoglycans in cardiovascular or renal disease.
5. Body Systems Associated with Proteoglycans
- Musculoskeletal system: Proteoglycans such as aggrecan, biglycan, decorin, perlecan, and versican significantly contribute to maintaining the health of articular cartilage and the cartilage repair process.
- Integumentary system (skin): Proteoglycans and glycosaminoglycans play an important role in skin as part of the support matrix of connective tissue, and may be related to cell–cell and cell–matrix interactions.
- Central nervous system: Neurocan and brevican are concentrated particularly in the specialized extracellular matrices of the brain.
- Cardiovascular system: Versican is enriched in large blood vessels.
- Renal system: Perlecan's charge-selective role in the glomerular basement membrane is integral to normal kidney filtration function.
- Connective tissue generally: Proteoglycans are glycosylated proteins which have covalently attached highly anionic glycosaminoglycans. Many forms of proteoglycans are present in virtually all extracellular matrices of connective tissues.
6. Dosage Forms and Dosages Reported in Studies
The following dosages and durations are drawn directly from peer-reviewed clinical studies. They do not represent prescriptive recommendations.
- 10 mg/day oral, 16 weeks: A randomized double-blind placebo-controlled clinical trial evaluated oral administration of proteoglycan at 10 mg/day on cartilage metabolism in individuals with knee joint discomfort but without a diagnosis of knee osteoarthritis.
- 10 mg/day oral, 24 weeks (diagnosed OA): A 24-week randomized, placebo-controlled, double-blind clinical trial administered 10 mg proteoglycan daily to patients with primary knee osteoarthritis.
- 16 mg proteoglycan + 16 mg type II collagen, 12 weeks: The Proteoglycan complex 80 product was administered as a tablet containing 16 mg of proteoglycan and 16 mg of type II collagen derived from salmon for 12 weeks in 60 healthy subjects aged 40 to 70.
- 20 mg/day oral, 56 days (skin outcomes): A 56-day randomized, double-blind, placebo-controlled trial involving 66 subjects aged 30–60 used a daily dose of 20 mg proteoglycan for skin parameters.
- 10 mg/kg body weight/day (oral, rat model): A daily oral dosage of 10 mg/kg of salmon proteoglycan, administered over 16 weeks, demonstrated a chondroprotective effect in a preclinical model.
In the preclinical 90-day toxicology study in rats, rats were administered salmon nasal cartilage extract once daily by oral gavage at doses of 0, 10.3, 20.6, or 41.2 mg/kg body weight/day.
7. Safety Considerations
Observed Safety Profile in Human Trials
Proteoglycan F was generally well-tolerated. No adverse effects were documented in treatment with salmon nasal proteoglycan and placebo extract. Changes in body weight, systolic and diastolic blood pressures, and pulse rate were minimal and within the reference range during the intervention in both groups. In addition, neither hepatotoxicity nor nephrotoxicity developed during the use of the product, supporting the biosafety of salmon nasal proteoglycan used as a supplement in the treatment of knee OA.
No test supplement-related adverse events were observed during the 16-week intervention in the Tomonaga et al. (2017) chondroprotective trial. Similarly, proteoglycan was well tolerated, with no adverse effects reported in the 56-day skin anti-aging trial (Bai et al., 2025).
Results of renal function (urea and creatinine levels) and liver function (levels of aspartate aminotransferase — AST, and alanine aminotransferase — ALT) showed no statistically significant difference in the above indicators within or between groups at evaluation time points of 4 weeks, 12 weeks, and 24 weeks compared to baseline (p > 0.05).
Preclinical Toxicology
A formal 90-day oral toxicity study in Sprague-Dawley rats reported reassuring findings: No deaths or test item-related clinical signs were observed. Sporadic changes in hematological, biochemical, urinary, or organ weight parameters occurred in some dose groups but were small in magnitude, showed no consistent dose-response relationship, and were not corroborated by histopathological alterations. Histopathology revealed only minimal findings, such as mild inflammation or congestion in the liver, kidneys, and lungs, occurring at low incidence and with similar frequency in both control and high-dose groups. Estrous cycles remained within normal limits, and recovery groups showed no evidence of delayed or irreversible toxicity. Based on these findings, the No Observed Adverse Effect Level (NOAEL) for the salmon nasal cartilage complex was determined to be 41.2 mg/kg body weight/day in Sprague-Dawley rats under the conditions of this study, supporting its safety for use as a food ingredient within the expected range of human intake.
Compliance and Dropout
One clinical trial reported good compliance (>95%) among participants receiving oral salmon nasal proteoglycan.
Limitations of the Safety Data
The evidence base remains limited. Many studies have small sample sizes or lack long-term follow-up, and the precise mechanisms by which dietary proteoglycans exert systemic effects are not yet fully understood. More rigorous, large-scale clinical trials are necessary to validate efficacy and safety for various health applications.
Persons with confirmed fish or shellfish allergies should exercise caution with salmon-derived proteoglycan products, as the source material is marine in origin. No drug–drug interaction data have been formally published in peer-reviewed clinical trials as of the available literature. Given the limited number and scale of human trials, long-term safety data beyond 24 weeks in human subjects have not been established in the published record.
8. Evidence Limitations and Research Gaps
Across all areas reviewed, several important limitations characterize the current body of evidence:
- Small sample sizes: Most human trials enroll fewer than 100 subjects, limiting statistical power and generalizability.
- Short durations: Clinical trials have ranged from 8 to 24 weeks; long-term effects and safety remain unstudied in humans.
- Geographic concentration: These studies were conducted predominantly on Japanese subjects, with limited research available on other populations.
- Mechanistic gaps: The precise mechanisms by which dietary proteoglycans exert systemic effects are not yet fully understood.
- Product heterogeneity: Due to variations in product manufacturing processes, clinical research specific to each proteoglycan product is necessary to explore its efficacy.
- Bioavailability: How intact proteoglycan macromolecules are absorbed, distributed, and utilized systemically following oral administration has not been established definitively in published human pharmacokinetic studies.
References
Go back